1.Comparison study of interferon-a combined chemotherapy versus chemotherapy only in patients with invasive uterine cervical cancer.
Hyun KIM ; Dong Hwi KIM ; Un Dong PARK
Korean Journal of Gynecologic Oncology and Colposcopy 1997;8(2):141-150
This study is to evaluate therapeutic effects between interferon-a combined chemotherapy and chemotherapy(5-fluorouracil, cisplatin) only in invasive uterine cervical cancer. The study included 35 cases of interferon-a combined chemotherapy group and 50 cases of chemotherapy(5-FU, cisplatin) only group. Then we analyzed the therapeutic effects with respect to size of tumor, number of lymphocyte subsets and NK activity, and SCC Ag(squamous cell carcinoma antigen) level in peripheral blood. (continue)
Drug Therapy*
;
Humans
;
Lymphocyte Subsets
;
Uterine Cervical Neoplasms*
2.Conservative treatment of cervical pregnancy.
Young Jun BYUNE ; Bae Geun YOON ; Dong Hwi KIM ; Un Dong PARK
Korean Journal of Obstetrics and Gynecology 1993;36(8):3307-3311
No abstract available.
Pregnancy*
3.Expression of bcl-2 and p53 Protein in Invasive Cervical Cancer.
Cheon Jun LEE ; Eun Mo AHN ; Tae Hong YEO ; Dong Hwi KIM ; Un Dong PARK
Korean Journal of Gynecologic Oncology and Colposcopy 1999;10(3):272-279
Recently, the bcl-2 and p53 protein have been recognized as important factors that is contributed to programmed cell death. The objective of this study was to evaluate the prognostic significance of bcl-2 and p53 protein expression in uterine cervical carcinoma. The expression of bcl-2 and p53 in 59 cases of uterine cervical carcinoma (stage IB to IIB) were surgically treated from January 1993 to June 1994. The expression of bcl-2 and p53 was examined by immunohistochemical method using formalin fixed paraffin embedded tissue specimens. The 48 cases were squamous cell carcinoma and 11 cases were adenocarcinoma. The results were as follows: 1. The expression rate of bcl-2 protein was 28.8%(17/59) and there was no significant correlaltion between the expression of bcl-2 protein and the clinicopathologic parameters (histologic type, grade, FIGO stage, cervical invasion depth, lymph node metastasis, parametrial invasion, tumor size, neoadjuvant chemotherapy response, recurrence, survival). 2. The expression rate of p53 protein was 32.2%(19/59) and there was no significant correlation between expression of p53 protein and the clinicopathologic parameters. 3. There was significant correlation between and expression of bcl-2 and p53 protein (P 0.05). In conclusion, bcl-2 and p53 protein are thought to be possible factors in the carcinogenesis of uterine cervical carcinoma and correlate with progression of it. But further study will be required to clarify the role of bcl-2 and p53 in carcinogenesis of the uterine cervix.
Adenocarcinoma
;
Carcinogenesis
;
Carcinoma, Squamous Cell
;
Cell Death
;
Cervix Uteri
;
Drug Therapy
;
Female
;
Formaldehyde
;
Lymph Nodes
;
Neoplasm Metastasis
;
Paraffin
;
Recurrence
;
Uterine Cervical Neoplasms*
4.Diagnostic Conization of the Cerivx.
Gun Sang YOO ; Dong Hwi KIM ; Eun Hee CHYU ; Un Dong PARK
Korean Journal of Gynecologic Oncology and Colposcopy 1996;7(2):77-83
To evaluate the effectiveness of conization in the diagnosis of cervical cancer, the histopathologic finding of 464 consecutive cases were analized with respect to the cytology, punch biopsy and hysterectomy. Cold knife conization was performed under direct visualization(naked eye conization) from January, 1987 to Octorber 1994 at department of Obstetrics and Gynecology, Kosin Medical Center. The results were summerized as follows : 1. The rate of agreement and underdiagnosis of between pap smear and naked eye conization were 43.7% and 47%. 2. The rate of agreement and underdiagnosis of between punch biopsy and naked eye conization were 64.5% and 21.8% 3. Subsequent hysterectomy was done on the 382 case and their incidence of residual disease rate was 44.2%(169 cases). Their incidence of residual lesion was increased with severity of the carcinomatous change. 4. The rate of complication undergoing conization was 8.4%(39 cases).
Biopsy
;
Conization*
;
Diagnosis
;
Gynecology
;
Hysterectomy
;
Incidence
;
Obstetrics
;
Uterine Cervical Neoplasms
6.Follow up Study of Second Look Laparotomy in Ovarian Cancer patients.
Jun Mo AN ; Dong Hwi KIM ; Hyun KIM ; Gun Sang YOO ; Choi In SEOK ; Eun Hee JOO ; Un Dong PARK
Korean Journal of Gynecologic Oncology and Colposcopy 1996;7(2):93-99
A study was to evaluate the efficacy and clinical utility of second look operation in the managements of malignant ovarian tumor at the Department of Obstetrics and Gynecology, Kosin medical colleage from January 1986 to September 1993. Of 220 patients diagnosed as ovarian cancer, 48 patients who had underwent primariy laparotomy were performed second look operation. Thirty-seven patients were found to have no evidence of disease. The result revealed that negative second look operation rate was noted 96.3% at stage I, 66.6% at stage II, 50.0% at stage III, and 42.9% at stage IV and total negative second look operation rate was 77.1%. The 2 year survival rate for stage I, II, III, IV were 85.2%, 66.6%, 50.0% and 42.9% respectively. The survival rate of negative second look operation was 86.5%, that of positive second look operation was 18.1%. In conclusion, second look operation in early stage ovarian cancer need to be justified.
Follow-Up Studies*
;
Gynecology
;
Humans
;
Laparotomy*
;
Obstetrics
;
Ovarian Neoplasms*
;
Survival Rate
7.A Clinicopathologic Study of 31 Cases with Ovarian Malignant Germ Cell Tumors.
Nam Won SEO ; Cheon Jun LEE ; Do Hyung KIM ; Un Mo AHN ; Tae Hong YEO ; Jun Houg KIM ; Sunn Ie AHN ; Dong Hwi KIM ; Un Dong PARK
Korean Journal of Obstetrics and Gynecology 2000;43(1):51-57
OBJECTIVE: The purpose of this study was to review the clinicopathologic features, recurrent rate, survival rate and controversable issues in the treatment of the ovarian malignant germ cell tumors. PATIENTS AND METHODS: From August, 1991 to November, 1998 thirty-one patients with malignant germ cell tumors of the ovary treated in the department of obstetrics and gynecology, Kosin University Medical college, were eligible and assessable. Demographic characteristics, symptoms, signs, stage, tumor grade, mode of therapy and results of follow up were reviewed retrospectively. RESULTS: The patients with malignant germ cell tumor constituted 6.37% of all ovarian malignancies during this period. Histologic subtypes were 8 dysgerminoma(25.8%), 7 endodermal sinus tumor(22.6%), 10 immature teratoma(32.3%), 3 mixed germ cell tumor(9.7%), 3 choriocarcinoma(9.7%). The age of the patients ranged from 10 to 40 years (mean +/-S.D.; 24.26 +/- 7.51). The most common symptom was abdominal pain(38.7%). Most had stageI(18 cases, 58.0%) or stageIII(5 cases, 16.2%) diseases. All patients underwent surgery as the initial treatment, and nine patients received more than one operation. Postoperative adjuvant chemotherapeutic regimens were VAC, VBP, EP, BEP, EMA, and EMA CO. The mean follow up duration was 26.0(+/- S.D.; +/- 20.3) months. The 2-year and 5-year survival rate were 91.97%(+/- S.E.; +/- 0.05) and 86.86%(+/- S.E.; +/- 0.07).
Endoderm
;
Female
;
Follow-Up Studies
;
Germ Cells*
;
Gynecology
;
Humans
;
Neoplasms, Germ Cell and Embryonal*
;
Obstetrics
;
Ovary
;
Retrospective Studies
;
Survival Rate
8.Taxol as Salvage Therapy in Patients with Recurrent Ovarian Carcinoma After First Line Chemotherapy.
Do Hyung KIM ; Sun Hwa NOH ; Dong Hwi KIM ; Un Dong PARK
Korean Journal of Gynecologic Oncology and Colposcopy 1998;9(2):163-167
As salvage therapy for recurrent ovarian cancer, Taxol has been tried alone or combined with cisplatin, or carboplatin. Paclitaxel (Taxol) is an antineoplastic agent; isoloated from the back of the western yew which acts as an antimicrotubule agent. In our study, 28 patients were eligible and assessable, Taxol was administered at a dose of 175 mg/m2, infused over 3hr every 21 days. A total of 161 courses of Taxol were infused, and the median treatmemt cycle was 6.25 cycles (1 to 16 cycles). The overall response rate was 21.4%, but we found higher response rate in sensitive group to platinum combined therapy than resistant. The median survival duration was 10.2 months and the median duration of follow up was 25.0 months. The worst severe toxicity was grade 4 leukopenia and expirement with sepsis. 39% of patients experienced myalgia and 25% experienced nausea, vomiting and diarrhea. Other adverse effects were not important or considerable. Taxol has been shown to be the most useful agent in patients with advanced ovarian cancer who had shown sensitivity with platinum previously, and Taxol has yielded low response rate in platinum-resistant patients. Further more study is repuired about Taxol itself, its optimal dose, combinding use with other antitumor agent, and as first line therapy in the treatment of advanced ovarian carcinoma.
Carboplatin
;
Cisplatin
;
Diarrhea
;
Drug Therapy*
;
Follow-Up Studies
;
Humans
;
Leukopenia
;
Myalgia
;
Nausea
;
Ovarian Neoplasms
;
Paclitaxel*
;
Platinum
;
Salvage Therapy*
;
Sepsis
;
Vomiting
9.Taxol as Salvage Therapy in Patients with Recurrent Ovarian Carcinoma After First Line Chemotherapy.
Do Hyung KIM ; Sun Hwa NOH ; Dong Hwi KIM ; Un Dong PARK
Korean Journal of Gynecologic Oncology and Colposcopy 1998;9(2):163-167
As salvage therapy for recurrent ovarian cancer, Taxol has been tried alone or combined with cisplatin, or carboplatin. Paclitaxel (Taxol) is an antineoplastic agent; isoloated from the back of the western yew which acts as an antimicrotubule agent. In our study, 28 patients were eligible and assessable, Taxol was administered at a dose of 175 mg/m2, infused over 3hr every 21 days. A total of 161 courses of Taxol were infused, and the median treatmemt cycle was 6.25 cycles (1 to 16 cycles). The overall response rate was 21.4%, but we found higher response rate in sensitive group to platinum combined therapy than resistant. The median survival duration was 10.2 months and the median duration of follow up was 25.0 months. The worst severe toxicity was grade 4 leukopenia and expirement with sepsis. 39% of patients experienced myalgia and 25% experienced nausea, vomiting and diarrhea. Other adverse effects were not important or considerable. Taxol has been shown to be the most useful agent in patients with advanced ovarian cancer who had shown sensitivity with platinum previously, and Taxol has yielded low response rate in platinum-resistant patients. Further more study is repuired about Taxol itself, its optimal dose, combinding use with other antitumor agent, and as first line therapy in the treatment of advanced ovarian carcinoma.
Carboplatin
;
Cisplatin
;
Diarrhea
;
Drug Therapy*
;
Follow-Up Studies
;
Humans
;
Leukopenia
;
Myalgia
;
Nausea
;
Ovarian Neoplasms
;
Paclitaxel*
;
Platinum
;
Salvage Therapy*
;
Sepsis
;
Vomiting
10.Urinary Metabolites and Neurobehavioral Test on Styrene Exposure Workers.
Chang Hee LEE ; Deog Hwan MOON ; Hun LEE ; Jun Han PARK ; Dae Hwan KIM ; Jong Tae LEE ; Jin Ho CHUN ; Hwi Dong KIM ; Chae Un LEE
Korean Journal of Preventive Medicine 1996;29(4):863-876
In order to prepare the fundamental data for the health promotion by assessing the exposure level of styrene, the author determined the concentration of mandelic acid and phenylglyoxylic acid in urine of 42 workers who were exposed to styrene by high performance liquid chromatography and surveyed 16 symptoms, by questionnaire and also tested neurobehavioral test(digit symbol, benton visual retention) in 2 FRP plants of Kyung Nam area from July to September, 1995. Control was sampled by age sex matching method. The concentration of styrene in air was determined by gas chromatography. The results were as follows; 1. Geometric mean concentration of styrene in air was 17.4ppm, geometric mean concentration of mandelic acid(MA) in urine were 404.3mg/g creatinine for exposure group, 46.4mg/g creatinine for control group, geometric mean concentration of phenylglyoxylic acid(PGA) in urine were 57.5mg/g creatinine for exposure group, 9.5mg/g creatinine for control group. Mean concentration of MA and PGA showed statistically significant difference between exposure group and control group(p<0.01). 2. Number of symptom were 2.9 for exposure group, 3.3 for control group, number of digit symbol were 24.1 for exposure group, 32.5 for control group, number of Benton visual retention test were 6.1 for exposure group, 6.0 for control group, respectively. As result of adjusting the education year, number of Benton visual retention test showed statistically significant difference between exposure group and control group(p<0.05). 3. Excellent correlation were observed between environmental styrene exposure and urinary MA(r=0.80), PGA(r=0.73), and MA+PGA(r=0.81).
Chromatography, Gas
;
Chromatography, Liquid
;
Creatinine
;
Education
;
Health Promotion
;
Surveys and Questionnaires
;
Styrene*